PRESS RELEASE published on 08/28/2025 at 20:00, 1 year ago Inside Information / Other news releases GenSight Biologics postpones the release of its 2025 half-year financial results to September 29, 2025, after the market closes, to ensure highest audit standards. No material issues reported. Audit Committee and Board meetings rescheduled Financial Results Transparency Postponement GenSight Biologics Audit Procedures
BRIEF published on 07/17/2025 at 15:05, 1 year 2 months ago GenSight Biologics: Publication of an article on the predictions of LUMEVOQ® gene therapy Gene Therapy GenSight Biologics NOHL LUMEVOQ Visual Acuity
PRESS RELEASE published on 07/17/2025 at 15:00, 1 year 2 months ago Inside Information / Other news releases GenSight Biologics announces publication on predictors of final visual outcome in patients treated with LUMEVOQ® gene therapy. Study identifies key factors for improved visual acuity post-treatment Gene Therapy GenSight Biologics LUMEVOQ Visual Outcome Predictive Factors
BRIEF published on 07/17/2025 at 08:05, 1 year 2 months ago GenSight Biologics raises 500,000 euros to strengthen its development Funding GenSight Biologics Phase III Gene Therapies LUMEVOQ
BRIEF published on 07/03/2025 at 21:24, 1 year 2 months ago GenSight Biologics completes private placement of nearly €4 million Private Placement Common Shares Euronext Funding GenSight Biologics
PRESS RELEASE published on 07/03/2025 at 21:19, 1 year 2 months ago Inside Information / Operations of the issuer (acquisitions, sales...) GenSight Biologics closes EUR 3.9M private placement with issuance of ordinary shares, pre-funded warrants, investor warrants. Funds to repay convertible bonds. Maxim Group, LLC acted as placement agent Private Placement Ordinary Shares GenSight Biologics Maxim Group EUR 3.9M
BRIEF published on 07/01/2025 at 08:59, 1 year 2 months ago GenSight Biologics raises nearly €4 million in private placement Private Placement Investment GenSight Biologics Euronext Shares LUMEVOQ ®
PRESS RELEASE published on 07/01/2025 at 08:54, 1 year 2 months ago Inside Information / Operations of the issuer (acquisitions, sales...) GenSight Biologics successfully completes private placement of nearly EUR 4 million, attracting new international investors. Funds to advance gene therapies for retinal diseases and CNS disorders Private Placement GenSight Biologics Gene Therapies Retinal Diseases CNS Disorders
BRIEF published on 06/26/2025 at 07:35, 1 year 2 months ago GenSight Biologics: Advances in Manufacturing Partnership with Catalent Gene Therapy GenSight Biologics LUMEVOQ® NOHL Catalent
PRESS RELEASE published on 06/26/2025 at 07:30, 1 year 2 months ago Inside Information / Other news releases GenSight Biologics achieves significant milestone with new manufacturing partnership with Catalent, successfully transferring upstream phase of LUMEVOQ® manufacturing process Gene Therapy GenSight Biologics LUMEVOQ Catalent Manufacturing Partnership
Published on 09/21/2026 at 15:45, 4 hours 42 minutes ago Datavault AI and Cutting-Edge Sports Management Announce Dream Bowl XV at AT&T Stadium and Launch First-of-Its-Kind Bowl Combine
Published on 09/21/2026 at 14:20, 6 hours 7 minutes ago Doctor's Choice(R) Clinically-Proven Scrubs Launching on Amazon Canada
Published on 09/21/2026 at 14:05, 6 hours 22 minutes ago Winners of this Year's Semmelweis-Richter International Journalism Award Announced
Published on 09/21/2026 at 14:00, 6 hours 27 minutes ago Dateline Files Motion to Resume Operations at Colosseum
Published on 09/21/2026 at 13:45, 6 hours 42 minutes ago Nine Mile Metals DDH WD-26-11 Intersects 2 High Grade VMS Zones Over 27.6M Including 3.08% CU-EQ Over 10.70M, 3.27% CU-EQ Over 9.30M and 4.30% CU-EQ Over 5.0M
Published on 09/21/2026 at 18:00, 2 hours 27 minutes ago Cham Swiss Properties places bond of CHF 100 million
Published on 09/21/2026 at 17:45, 2 hours 42 minutes ago EQS-Adhoc: Airbus reports share buyback transactions 11-18 September 2026
Published on 09/21/2026 at 17:45, 2 hours 42 minutes ago Charwood Energy continues to grow at a strong pace. H1 revenue up +43% to €5.6m.
Published on 09/21/2026 at 17:00, 3 hours 27 minutes ago Menarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
Published on 09/21/2026 at 18:19, 2 hours 8 minutes ago Reporting on share buyback transactions carried out between September 14 and September 18, 2026
Published on 09/21/2026 at 18:01, 2 hours 25 minutes ago Partnership agreement signed between Manitou Group and HD Construction Equipment
Published on 09/21/2026 at 17:46, 2 hours 41 minutes ago WEB SA - STATUTORY HALF-YEAR RESULTS AS OF 30/06/2026
Published on 09/21/2026 at 07:00, 13 hours 27 minutes ago Peugeot Invest takes a stake in Mérieux NutriSciences
